LBX(SH:603883)2023-04-27 16:00Financial Performance - The company reported a total revenue of RMB 10.5 billion for the fiscal year 2022, representing a year-on-year growth of 15%[19]. - The company's operating revenue for 2022 was CNY 20,175,519,303, representing a year-over-year increase of 28.54%[20]. - Net profit attributable to shareholders for 2022 was CNY 784,961,520, up 17.29% from the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 735,724,494, reflecting a growth of 28.52% year-over-year[20]. - The company's revenue exceeded 20 billion yuan, with a total of 10,783 stores, including 7,649 direct-operated and 3,134 franchised stores[29]. - The retail segment generated revenue of CNY 17,597,333,924, with a gross margin of 34.56%, reflecting a decrease of 0.17 percentage points year-on-year[62]. - The company achieved a net profit of 17.88 million yuan for the year 2022, exceeding the forecast of 14.65 million yuan, representing a 21.5% increase[178]. Dividend Distribution - The proposed cash dividend distribution is RMB 5 per 10 shares, totaling RMB 292,403,451, which accounts for 37.25% of the net profit attributable to shareholders for the year[4]. - The company implemented a cash dividend policy, distributing a cash dividend of RMB 0.5 per share, totaling RMB 223,978,654.50, and a capital reserve increase of 0.3 shares per share, resulting in a total share capital of 582,344,502 shares[137]. Share Capital and Structure - The total share capital as of March 31, 2023, is 584,902,902 shares, after deducting 96,000 restricted shares to be repurchased[4]. - The total number of shares increased to 584,902,902 after the issuance of 39,927,820 new shares and a stock dividend distribution[195]. - The company completed a non-public issuance of 39,927,820 shares on February 10, 2022, increasing total shares from 408,673,661 to 448,601,481[198]. - The company granted 2,558,400 restricted shares to 305 incentive recipients as part of its incentive plan[195]. Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[6]. - The company has outlined various risks and countermeasures in the management discussion section of the report[6]. - The company faces industry policy risks that could impact its operations and market conditions[102]. - The company will closely monitor policy changes and engage industry experts to enhance its understanding and compliance, ensuring proactive adjustments to maintain operational standards[103]. Corporate Governance - The board of directors and management have ensured the authenticity, accuracy, and completeness of the annual report[2]. - The company conducted 4 shareholder meetings during the reporting period, ensuring compliance with legal requirements and maintaining transparency in decision-making[105]. - The board of directors held 13 meetings, with all members fulfilling their duties diligently and adhering to relevant regulations[105]. - The supervisory board convened 10 meetings, actively safeguarding the rights of shareholders and ensuring corporate governance[105]. Market Expansion and Strategy - The company plans to expand its market presence in the northern regions of China, targeting a 20% increase in market share by 2025[19]. - The company is exploring potential acquisitions to enhance its supply chain capabilities and expand its product offerings[19]. - The company aims to capture the prescription drug market by leveraging its high-standard dual-channel stores and DTP stores in response to the trend of prescription outflow[100]. - The company is actively expanding its market presence through a combination of self-operated, franchise, and alliance models, enhancing its competitive edge in the pharmaceutical retail sector[54]. Research and Development - The company has invested RMB 200 million in R&D for innovative pharmacy technologies, aiming to enhance customer service and operational efficiency[19]. - Research and development expenses totaled CNY 111,080,756, accounting for 0.55% of total revenue, with 97.99% of R&D costs capitalized[73]. - The company is investing in technology development, allocating 500 million RMB towards R&D initiatives in the upcoming year[114]. Community Engagement and Social Responsibility - The company invested a total of 3.7866 million yuan in external donations and public welfare projects during the reporting period[152]. - The company donated medical supplies worth CNY 1 million to support pandemic prevention efforts in various regions, including CNY 880,000 worth of supplies to Shaoyang County[153]. - The company supported the construction of cultural squares and road repairs in Dazhuiping Village with a donation of CNY 1 million through the Xixiang Charity Fund[154]. Employee Development and Training - The company achieved a total of 14,969,746 training hours across its workforce, averaging approximately 235 hours of training per employee[133]. - The company developed 819 new courses and launched 1,317 courses on its internal learning platform to enhance employee skills[133]. - The company has established a digital talent training ecosystem to support personalized online learning and precise empowerment[134]. Financial Health and Cash Flow - The company's net cash flow from operating activities was CNY 2,314,315,009, showing a slight increase of 0.70% compared to the previous year[20]. - The net cash flow from investing activities improved significantly, with a decrease in outflow to (¥1,456,649,394) from (¥2,002,151,349), representing a 27.25% reduction[76]. - The total monetary funds at the end of the period reached ¥2,410,922,260, a 71.12% increase from ¥1,408,874,821 in the previous year[78].